Mesenchymal Stem Cells Hold Promise for Osteoarthritis and More Chronic Diseases

Video

Cynata Therapeutics' Ross Macdonald, PhD, discusses the company's pipeline and clinical-phase trials.

Stem cells have been a hot-button topic for some time now, the subject of quite a bit of hype and controversy, as well. As the dust continues to settle, it has become very clear that specifically mesenchymal stem cells represent a very promising therapeutic modality for diseases that are currently considered untreatable.

Cynata Therapeutics has developed a novel manufacturing platform, called Cymerus, that utilizes mesenchymoangioblasts derived from induced pluripotent stem cells to both economically and efficiently produce therapeutic mesenchymal stem cells that are of consistent quality.

The biotechnology company is pursuing the investigation of mesenchymal stem cell-based therapeutics in several indications, including osteoarthritis, critical limb ischemia, graft-versus-host disease, and acute respiratory distress syndrome, among others.

GeneTherapyLive sat down with Cynata's managing director and chief executive officer Ross Macdonald, PhD, to learn more about the company's clinical pipeline.

Related Videos
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
© 2024 MJH Life Sciences

All rights reserved.